12,372 trials
Vitamin D Deficiency
Primary: Maternal Serum and Neonatal Serum 25-hydroxyvitamin D Measurement — 21.5; 20.5; 19.6; 40.7 nmol/L
Pregnancy
Primary: The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy. — 0.12; 0.12 6 month probability of pregnancy
Secondary Hyperparathyroidism · Hemodialysis
Primary: Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without Hypercalcemia — 27.7; 30.5 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS): Independent-Assessment — 9.1; 9.3 months — p=0.8
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 52 — -0.82; -0.93; -0.81 Percent
Affective Disorders
Primary: 21 Item Hamilton Depression Rating Scale — 13.6; 11.0 Units on Hamilton Depression Scale
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Rhinitis
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) — 15; 17; 32; 0 participants
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 26 (Main Study) — 0.14; -0.77; -1.03 Percent — p=<0.001
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 24 — -0.14; -0.66 Percent — p=<0.0001
Spinal Cord Injury · Muscle Spasticity
Primary: Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity — -0.19; -0.15 units on a scale
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
Primary Hypercholesterolemia
Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -27.70; -0.95 Percent Change — p=<0.001